Section Arrow
Quote
DRMA.NASDAQ
- Dermata Therapeutics Inc
Quotes are at least 15-min delayed:2026/01/07 16:04 EST
After Hours
Last
 2.18
0 (0.00%)
Bid
2.18
Ask
2.2
High 2.18 
Low 2.18 
Volume 2 
Regular Hours (Closed)
Last
 2.18
-0.08 (-3.54%)
Day High 
2.2999 
Prev. Close
2.26 
1-M High
2.98 
Volume 
100.89K 
Bid
2.18
Ask
2.2
Day Low
2.14 
Open
2.22 
1-M Low
1.58 
Market Cap 
7.23M 
Currency 美元 
P/E 0.15 
%Yield -- 
10-SMA 2.16 
20-SMA 2.35 
50-SMA 2.8 
52-W High 23.7 
52-W Low 1.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
15.24/-0.82
Enterprise Value
7.23M
Balance Sheet
Book Value Per Share
1.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1316+0.0266+25.33%-- 
After Hours 0.132 +0.0064 +5.10%
ERASErasca5.425+1.795+49.45%-- 
After Hours 4.49 -0.68 -13.15%
RXRXRecursion Pharmaceuticals4.885+0.335+7.36%-- 
After Hours 4.86 +0.01 +0.21%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
After Hours 13.73 0 0.00%
GLUEMonte Rosa Therapeutics23.3816+7.3716+46.04%54.09PE
After Hours 22.86 -0.42 -1.80%
Industry overview quotes are at least 15 minutes delayed
Business Description
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase3 data from its STAR-1 clinical trial in March 2025.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.